Jamjoom Pharma Q4 2024: What are analysts predicting?
In this report, Argaam highlights the expected results of Jamjoom Pharmaceuticals Factory Co. in Q4 2024, as well as its key events, quarterly sales and profit, and performance indicators.
The company is projected to post a 22% year-on-year (YoY) jump in the fourth-quarter revenue to SAR 253.75 million.
Quarter Revenue Changes (M Riyal)
| Item | Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Sales | 208.96 | 385.46 | 345.74 | 327.58 | 253.75 |
| Change % | 6.16% | 28.12% | 15.86% | 11.95% | 21.44% |
| Income from Affiliate | 5.33 | 1.76 | 2.01 | 7.07 | NA |
| Change % | NA | NA | NA | NA | NA |
Quarter Net Income Changes (M Riyal)
| Item | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Net Income | 44.48 | 102.97 | 106.95 | 94.99 | 55.80 |
| Extraordinary income/expense | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Net Profit Before Unusual Items | 44.48 | 102.97 | 106.95 | 94.99 | - |
| EPS Before Unusual Items (Riyal/Share) | 0.64 | 1.47 | 1.53 | 1.36 | 0.80 |
Key events in Q4 2024
The company's key performance indicators remained steady, standing on par with the results of the first nine months of 2024 and projections for the remainder of the year.
Quarterly Profit and Revenue (M Riyal)
Average forecasts
The company is forecast to record a net profit of SAR 55.8 million in Q4 2024, a rise of 25.4% from SAR 44.5 million in Q4 2023, based on average estimates by five research houses.
Quarterly Actuals vs Estimates (M Riyal)
Average Estimate (M Riyal)
| Analyst | Million Riyals |
|---|---|
| United Securities Company | 69.00 |
| GIB Capital LLC | 57.00 |
| Osool and Bakheet Investment Co. | 55.21 |
| SNB Capital Company | 49.80 |
| Al Rajhi Capital Company | 48.00 |
| Average | 55.80 |
| Net Profit Before Unusual Items (2023 - Q4) | 44.48 |
| Change % | 25.44% |
Performance & profitability indicators
The following table shows the stock performance trailing 12 months (TTM) and year to date, as well as its P/E and earnings per share:
Stock Performance
| Item | The Company | TASI |
|---|---|---|
| YTD | 9.70 % | 2.80 % |
| Change(12M) | (7.74 %) | 3.58 % |
| Previous Close | 163.40 | 12,415.49 |
| Recurring P/E (x) | 32.08 | 25.14 |
| EPS (TTM) before unusual items (SAR/Share) | 4.99 | - |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}
Valuation Data (Latest Share Price)
| P/E (TTM) | 23.01 |
| Recurring P/E | 23.01 |
| P/BV | 6.32 |
| Dividend Yield | 2.81 % |
| Market Cap. (M) | 10,927.01 |
| Return on Average Assets | 23.66 % |
| Return on Average Equity | 29.00 % |
Most Read
- MCDC consortium wins SAR 6B contract to develop 2 districts in Makkah
- From Masar Makkah to New destinations Umm Al Qura for Development & Construction Launches New Five-Year Strategy and announces Its Second Destination in Makkah
- Home loans to individuals up to SAR 6.3B in April: SAMA
- Al Majdiah, First Avenue win SAR 2B development project in Makkah
- Saudi Steel Pipe signs SAR 65M contract with Aramco
Comments Analysis: